

2 February 2024

Completion of Share Consolidation

Melodiol Global Health Limited (ASX:ME1) ('Melodiol' or 'the Company') advises that following shareholder approval at the General Meeting held on 23 January 2024, the consolidation of the issued capital of the Company on the basis of 1 security for every 20 securities is now complete.

The post-consolidation securities on issue are as follows:-

Security Code	Security Name	Balance
ME1	ORDINARY FULLY PAID SHARES	245,825,445
ME1O	LISTED OPT EXP 2/11/2024 @ \$5.00	38,981,457
ME1OD	LISTED OPT EXP 31/01/2027 @ \$1.60	66,523,452
ME1OE	LISTED OPT EXP 13/11/2028 @ \$0.12	9,234,908
ME1OPT32	UNL OPT EXP 23/12/2023 @ \$4.00	41,666
ME1OPT33	UNL OPT EXP 23/12/2025 @ \$0.78	1,500,000
ME1OPT38	UNL OPT EXP 14/07/2024 @ \$7.60	600,000
ME1OPT39	UNL OPT EXP 01/08/2024 @ \$3.00	600,000
ME1OPT40	UNL OPT EXP 01/08/2024 @ \$3.60	600,000
ME1OPT41	UNL OPT EXP 06/09/2024 @ \$3.60	500,000
ME1OPT42	UNL OPT EXP 06/09/2024 @ \$5.00	500,000
ME1OPT43	UNL OPT EXP 25/10/2024 @ \$2.75	50,000
ME1OPT45	UNL OPT EXP 12/06/2024 @ \$2.80	5,797,079
ME1OPT48	UNL OPT EXP 28/06/2024 @ \$8.00	31,312
ME1OPT49	UNL OPT EXP 28/06/2024 @ \$26.80	31,312
ME1OPT50	UNL OPT EXP 28/06/2024 @ \$40.00	31,312
ME1OPT51	UNL OPT EXP 28/06/2024 @ \$53.00	31,312
ME1OPT52	UNL OPT EXP 28/06/2025 @ \$0.40	82,413
ME1OPT53	UNL OPT EXP 08/06/2024 @ \$7.60	1,399,916
ME1OPT54	UNL OPT EXP 24/08/2024 @ \$0.60	12,953,911
ME1OPT55	UNL OPT EXP 10/10/2024 @ \$0.80	100,000
ME1OPT57	UNL OPT EXP 16/11/2027 @ \$0.44	532,700
ME1OPT58	UNL OPT EXP 30/11/2024 @ \$0.80	150,000
ME1PERR45	PERFORMANCE RIGHTS EXP 27/07/2025	25,000
ME1PERR46	PERFORMANCE RIGHTS EXP 27/07/2026	25,000
ME1PERR47	PERFORMANCE RIGHTS EXP 27/07/2027	50,000
ME1PERR48	PERFORMANCE RIGHTS EXP 14/07/2025	25,000
ME1PERR49	PERFORMANCE RIGHTS EXP 14/07/2026	25,000
ME1PERR50	PERFORMANCE RIGHTS EXP 14/07/2027	50,000
ME1PERR52	PERFORMANCE RIGHTS EXP 27/10/2028	2,500,000
ME1PERR54	PERFORMANCE RIGHTS EXP 27/10/2028	1,500,000
ME1PERS2	PERFORMANCE SHARES EXP 25/10/2024	150,000
ME1PERS3	PERFORMANCE SHARES EXP 25/10/2026	150,000

ME1CON7	CONVERTIBLE NOTES	17,499
ME1CON8	CONVERTIBLE NOTES	8,499

-Ends-

Authority and Contact Details

This announcement has been authorised for release by the Company Secretary.

For further information, please contact:

Investor Enquiries

Melodiol Global Health Limited

E: info@cresopharma.com

P: +61 (0) 497 571 532

About Melodiol

Melodiol Global Health Limited (ASX:ME1) brings the best of cannabis and other plant-based products to better the lives of people and animals. Melodiol strives for the highest quality in its products. It develops cannabis, hemp-derived and other plant based therapeutic, nutraceutical, and lifestyle products with wide consumer reach.

To learn more please visit: <https://melodiolglobalhealth.com/>

Melodiol offices:

Australia: Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

Canada: 59 Payzant Drive, Windsor, Nova Scotia, B0N 2T0 and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0